Form 4: Ultragenyx CFO Sells Shares for Tax Obligations

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported a planned sale of 7,942 shares of common stock at $31.51 per share to cover tax obligations from RSU vesting.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a planned sale of 7,942 shares of common stock.
• The transaction is scheduled for October 13, 2025, at a price of $31.51 per share.
• This sale is being conducted pursuant to a Rule 10b5-1 trading plan and is intended to cover tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs).
• Following this planned transaction, Horn is expected to beneficially own 98,227 shares of common stock.

Sentiment

Score: 6

Explanation: The transaction is a non-discretionary, pre-planned sale of shares by the CFO to cover tax obligations arising from RSU vesting, which is a routine compensation event. The underlying RSU vesting is positive for the executive, making the overall sentiment slightly positive.

Positives

• The transaction is a result of the vesting of Restricted Stock Units (RSUs), indicating the realization of compensation for the Chief Financial Officer.
• The sale is executed under a Rule 10b5-1 trading plan, which provides an affirmative defense against insider trading allegations, demonstrating pre-planned and transparent executive stock management.

Negatives

• The Chief Financial Officer's direct beneficial ownership of common stock will decrease by 7,942 shares following the transaction.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Howard Horn, Chief Financial Officer, reported a planned sale of Ultragenyx Pharmaceutical Inc. common stock.

Stakeholder Impact

• Shareholders: The planned sale represents a minor reduction in insider ownership, but it is for a non-discretionary tax purpose and is pre-planned, so it is unlikely to signal any change in management confidence. It reflects the realization of executive compensation.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by the Chief Financial Officer to cover tax obligations from RSU vesting, executed under a Rule 10b5-1 plan. This administrative transaction does not reflect a change in management's outlook or a discretionary divestment, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Ultragenyx, RARE, Howard Horn, CFO, stock sale, RSU, tax withholding, insider transaction, Form 4, 10b5-1 plan